Trial · NCT02829996
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
NCT02829996, Phase 2, Completed, Inotek Pharmaceuticals Corporation; results first posted 2018-02-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG. Trials, record NCT02829996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02829996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
- NCT number
- NCT02829996
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 201 participants, actual
- Lead sponsor
- Inotek Pharmaceuticals Corporation
- Conditions
- Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Interventions
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD, latanoprost 0.005% QD, latanoprost 0.0025% QD
- First posted
- 2016-07-12
- Last updated
- 2018-02-15
- Results first posted
- 2018-02-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Intraocular Pressure (IOP) | Two Months | Daily change from diurnal baseline in IOP |
| Other | Safety Parameters, Including Treatment Emergent Adverse Events, to Assess Tolerability and Safety. | Through Study Completion, up to 9 weeks. | Collection of safety parameters, including treatment emergent adverse events, laboratory assessments, to assess tolerability and safety. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Intraocular Pressure (IOP) | Two Months | Intent to treat | mm of mercury | MEAN |
| OTHER_PRE_SPECIFIED | Safety Parameters, Including Treatment Emergent Adverse Events, to Assess Tolerability and Safety. | Through Study Completion, up to 9 weeks. |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Intraocular Pressure (IOP) | Trabodenoson 6.0% / Latanoprost 0.005% QD | -6.4 | Standard Error 0.48 | mm of mercury | |
| Mean Intraocular Pressure (IOP) | Trabodenoson 3.0% / Latanoprost 0.005% QD | -6.8 | Standard Error 0.56 | mm of mercury | |
| Mean Intraocular Pressure (IOP) | Trabodenoson 6.0% / Latanoprost 0.0025% QD | -6.4 | Standard Error 0.56 | mm of mercury | |
| Mean Intraocular Pressure (IOP) | Latanoprost 0.005% QD | -7.1 | Standard Error 0.46 | mm of mercury | |
| Mean Intraocular Pressure (IOP) | Latanoprost 0.0025% QD | -5.9 | Standard Error 0.53 | mm of mercury |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Trabodenoson 6.0% / Latanoprost 0.005% QD | 39 | |
| Overall Study | STARTED | Trabodenoson 3.0% / Latanoprost 0.005% QD | 39 | |
| Overall Study | STARTED | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 40 | |
| Overall Study | STARTED | Latanoprost 0.005% QD | 41 | |
| Overall Study | STARTED | Latanoprost 0.0025% QD | 42 | |
| Overall Study | COMPLETED | Trabodenoson 6.0% / Latanoprost 0.005% QD | 38 | |
| Overall Study | COMPLETED | Trabodenoson 3.0% / Latanoprost 0.005% QD | 39 | |
| Overall Study | COMPLETED | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 40 | |
| Overall Study | COMPLETED | Latanoprost 0.005% QD | 41 | |
| Overall Study | COMPLETED | Latanoprost 0.0025% QD | 42 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events25
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | UTI | Infections and infestations | Trabodenoson 6.0% / Latanoprost 0.005% QD | 4 | 39 | 4 |
| other | UTI | Infections and infestations | Trabodenoson 3.0% / Latanoprost 0.005% QD | 1 | 39 | 1 |
| other | UTI | Infections and infestations | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 1 | 40 | 1 |
| other | UTI | Infections and infestations | Latanoprost 0.005% QD | 1 | 41 | 1 |
| other | UTI | Infections and infestations | Latanoprost 0.0025% QD | 2 | 42 | 2 |
| other | Upper Respiratory Infection | Infections and infestations | Trabodenoson 6.0% / Latanoprost 0.005% QD | 1 | 39 | 1 |
| other | Upper Respiratory Infection | Infections and infestations | Trabodenoson 3.0% / Latanoprost 0.005% QD | 0 | 39 | 0 |
| other | Upper Respiratory Infection | Infections and infestations | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 2 | 40 | 2 |
| other | Upper Respiratory Infection | Infections and infestations | Latanoprost 0.005% QD | 2 | 41 | 2 |
| other | Upper Respiratory Infection | Infections and infestations | Latanoprost 0.0025% QD | 1 | 42 | 2 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 adverse eventsAdverse event totals15
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Trabodenoson 6.0% / Latanoprost 0.005% QD | 0 | 39 |
| Total, all-cause mortality | Trabodenoson 3.0% / Latanoprost 0.005% QD | 0 | 39 |
| Total, all-cause mortality | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 0 | 40 |
| Total, all-cause mortality | Latanoprost 0.005% QD | 0 | 41 |
| Total, all-cause mortality | Latanoprost 0.0025% QD | 0 | 42 |
| Total, other adverse events | Trabodenoson 6.0% / Latanoprost 0.005% QD | 9 | 39 |
| Total, other adverse events | Trabodenoson 3.0% / Latanoprost 0.005% QD | 5 | 39 |
| Total, other adverse events | Trabodenoson 6.0% / Latanoprost 0.0025% QD | 6 | 40 |
| Total, other adverse events | Latanoprost 0.005% QD | 3 | 41 |
| Total, other adverse events | Latanoprost 0.0025% QD | 5 | 42 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02829996
GET https://conductscience.org/api/trials/v1/NCT02829996/events?page=2